pioglitazone has been researched along with Cardiac Hypertrophy in 12 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo." | 7.73 | [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005) |
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 7.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| " Here we investigated the effect of pioglitazone on angiotensin II (Ang II)-induced cardiac hypertrophy and assessed the potential contribution of adiponectin to the action of pioglitazone on the heart." | 3.76 | Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. ( Cheng, X; Furukawa, M; Li, P; Murohara, T; Nagata, K; Ohashi, T; Ouchi, N; Shibata, R; Shimano, M; Unno, K, 2010) |
| "Wild-type cardiomyocyte- and macrophage-specific PPARgamma(-/-) mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPARgamma ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPARgamma in cardiac fibrosis." | 3.74 | Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. ( Caglayan, E; Collins, AR; Erdmann, E; Hsueh, WA; Liu, J; Lyon, CJ; Peterson, LE; Rosenkranz, S; Ross, RS; Stauber, B; Tangirala, RK; Yin, F, 2008) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "To investigate the effects of pioglitazone on cardiac hypertrophy in vitro and in vivo." | 3.73 | [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo]. ( Liu, YX; Wu, SM; Ye, P; Zhang, C, 2005) |
| "Endothelin-1 (ET-1) causes cardiac hypertrophy, and ET receptor antagonists inhibit the development of cardiac hypertrophy in vitro and in vivo." | 3.71 | Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| " In the present study, we examined the role of PPARgamma in angiotensin II (Ang II)-induced hypertrophy of neonatal rat cardiac myocytes and in pressure overload-induced cardiac hypertrophy of mice." | 3.71 | Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. ( Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H, 2002) |
| "Rosiglitazone treatment induced volume expansion and CH in wild-type and PPARĪ³ heterozygous knockout (Pparg(+/-)) mice, but not in mice defective for ligand binding (Pparg(P465L/+))." | 1.40 | Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. ( Chang, CS; Chen, JY; Ho, LC; Maeda, N; Pandya, K; Sung, JM; Tsai, PJ; Tsai, YS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, WY | 1 |
| Zhang, N | 1 |
| Li, LL | 1 |
| Ma, ZG | 1 |
| Xu, M | 1 |
| Yuan, YP | 1 |
| Deng, W | 1 |
| Tang, QZ | 1 |
| Liu, Y | 2 |
| Yan, X | 1 |
| Mao, G | 1 |
| Fang, L | 1 |
| Zhao, B | 1 |
| Tang, H | 1 |
| Wang, N | 1 |
| Chang, CS | 1 |
| Tsai, PJ | 1 |
| Sung, JM | 1 |
| Chen, JY | 1 |
| Ho, LC | 1 |
| Pandya, K | 1 |
| Maeda, N | 1 |
| Tsai, YS | 1 |
| Verschuren, L | 1 |
| Wielinga, PY | 1 |
| Kelder, T | 1 |
| Radonjic, M | 1 |
| Salic, K | 1 |
| Kleemann, R | 1 |
| van Ommen, B | 1 |
| Kooistra, T | 1 |
| Caglayan, E | 1 |
| Stauber, B | 1 |
| Collins, AR | 1 |
| Lyon, CJ | 1 |
| Yin, F | 1 |
| Liu, J | 2 |
| Rosenkranz, S | 1 |
| Erdmann, E | 1 |
| Peterson, LE | 1 |
| Ross, RS | 1 |
| Tangirala, RK | 1 |
| Hsueh, WA | 1 |
| Li, P | 1 |
| Shibata, R | 1 |
| Unno, K | 1 |
| Shimano, M | 1 |
| Furukawa, M | 1 |
| Ohashi, T | 1 |
| Cheng, X | 1 |
| Nagata, K | 1 |
| Ouchi, N | 1 |
| Murohara, T | 1 |
| Ye, P | 2 |
| Zhang, C | 1 |
| Wu, SM | 2 |
| Liu, YX | 1 |
| Sakai, S | 1 |
| Miyauchi, T | 1 |
| Irukayama-Tomobe, Y | 1 |
| Ogata, T | 1 |
| Goto, K | 1 |
| Yamaguchi, I | 1 |
| Yang, W | 1 |
| Sheng, L | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Liu, Z | 1 |
| Huang, F | 1 |
| Xing, Z | 1 |
| Wang, H | 1 |
| Li, Z | 1 |
| Asakawa, M | 1 |
| Takano, H | 1 |
| Nagai, T | 1 |
| Uozumi, H | 1 |
| Hasegawa, H | 1 |
| Kubota, N | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Kadowaki, T | 1 |
| Komuro, I | 1 |
12 other studies available for pioglitazone and Cardiac Hypertrophy
| Article | Year |
|---|---|
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload.
Topics: Anilides; Animals; Cardiomegaly; Cell Differentiation; Echocardiography; Fibrosis; Hemodynamics; Hum | 2018 |
Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones.
Topics: 5' Flanking Region; Adenosine Monophosphate; Adenylosuccinate Synthase; Animals; Cardiomegaly; Gene | 2013 |
Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
Topics: Animals; Cardiac Volume; Cardiomegaly; Diuretics; Extracellular Signal-Regulated MAP Kinases; Furose | 2014 |
A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.
Topics: Animals; Cardiomegaly; Diet, High-Fat; Gene Expression Profiling; Gene Expression Regulation; Genome | 2014 |
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
Topics: Adiponectin; Angiotensin II; Animals; Cardiomegaly; Chemotaxis; Female; Fibrosis; Hypoglycemic Agent | 2008 |
Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone.
Topics: Adiponectin; AMP-Activated Protein Kinases; Angiotensin II; Animals; Blotting, Western; Cardiomegaly | 2010 |
[Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cell Line; Cytokines; Disease Models, Animal; Inte | 2005 |
Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Cardiomegaly; Chromans; Endothelin-1; Endothelins; Male; Natriuretic | 2002 |
Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Cardiomegaly; Cells, C | 2006 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Pioglitazone inhibits hypertrophy induced by high glucose and insulin in cultured neonatal rat cardiomyocytes.
Topics: Animals; Animals, Newborn; Atrial Natriuretic Factor; Cardiomegaly; Cell Size; Cells, Cultured; Cyto | 2007 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Ce | 2002 |